However, a 2020 nationwide study from U.S. Veterans Affairs, which included 537,980 patients with ASCVD and T2DM, found that the prescription of SGLT2i or GLP-1 RA remained low at 19% (21). The gene discussed is GLP1R; the disease is atherosclerosis.